← Back
Data updated: Jun 28, 2026
NITROUS OXIDE CORP
Pharma Pharmaceuticals
NITROUS OXIDE CORP is a pharmaceutical company with 1 FDA-approved products.
2013
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
NITROUS OXIDE CORP's Key Drugs
NITROUS OXIDE CORP's core commercial portfolio centers on NITROUS OXIDE, USP — its most strategically important drugs approved in the last 15 years.
NITROUS OXIDE CORP's Recent FDA Approvals
New NDA/BLA approvals for NITROUS OXIDE CORP over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
NITROUS OXIDE CORP's Therapeutic Areas
Disease areas where NITROUS OXIDE CORP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
NITROUS OXIDE CORP Pipeline Snapshot
Active clinical trials for NITROUS OXIDE CORP across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • NITROUS OXIDE, USP leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2013-09-03
- Latest
- 2013-09-03
- Applications
- 1